Abstract: Skin-contact products with a transpiration function such as medical devices or medicinal products, of which face masks, aspirators, ventilators, breast pumps or wound dressings are examples are described especially a skin-contact product with a transpiration function with an improved microclimate at a patient interface material-skin contact area. In an embodiment a material system is described that comprises a hydrophobic silicone base material and a hydrophilic silicone material that is combined with the hydrophobic base material.

Abstract: Skin-contact products with a transpiration function such as medical devices or medicinal products, of which face masks, aspirators, ventilators, breast pumps or wound dressings are examples are described especially a skin-contact product with a transpiration function with an improved microclimate at a patient interface material -skin contact area. In an embodiment a material system is described that comprises a hydrophobic silicone base material and a hydrophilic silicone material that is combined with the hydrophobic base material.

Abstract: Skin-contact products with a transpiration function such as medical devices or medicinal products, of which face masks, aspirators, ventilators, breast pumps or wound dressings are examples are described especially a skin-contact product with a transpiration function with an improved microclimate at a patient interface material-skin contact area. In an embodiment a material system is described that comprises a hydrophobic silicone base material and a hydrophilic silicone material that is combined with the hydrophobic base material.

Abstract: This invention relates to medical, health care and non-medical devices comprising a rubbery or elastomeric polymer material taking up more than 5% by weight of water and at most 500% by weight of water after immersion in demineralized water at room temperature for a sufficient time to reach saturation. The material may be in the form of a foam, or in the form of a coating adapted for adhesion to a substrate, or in the form of a sheet, or in the form of a fiber, and may comprise: —repeating units from one or more hydrophobic organic monomers, and —repeating units from one or more monomers (a) being modified with one or more hydrophilic side groups.

Abstract: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.

Abstract: Skin-contact products with a transpiration function such as medical devices or medicinal products, of which face masks, aspirators, ventilators, breast pumps or wound dressings are examples are described especially a skin-contact product with a transpiration function with an improved microclimate at a patient interface material-skin contact area. In an embodiment a material system is described that comprises a hydrophobic silicone base material and a hydrophilic silicone material that is combined with the hydrophobic base material.

Abstract: This invention relates to a rubbery or elastomeric polymer material taking up more than 5% by weight of water and at most 500% by weight of water after immersion in demineralized water at room temperature for a sufficient time to reach saturation, comprising: (a) repeating units from one or more hydrophobic organic monomers, and (b) repeating units from one or more monomers (a) being modified with one or more hydrophilic side groups. The rubbery or elastomeric polymer material may be in the form of a sheet, a foam, a coating adapted for adhesion to a substrate, or a fiber. This invention also relates to processes, polymerizable compositions, and foaming compositions for producing such rubbery or elastomeric polymer materials.

Abstract: This invention relates to medical, health care and non-medical devices comprising a rubbery or elastomeric polymer material taking up more than 5% by weight of water and at most 500% by weight of water after immersion in demineralized water at room temperature for a sufficient time to reach saturation. The material may be in the form of a foam, or in the form of a coating adapted for adhesion to a substrate, or in the form of a sheet, or in the form of a fiber, and may comprise: —repeating units from one or more hydrophobic organic monomers, and —repeating units from one or more monomers (a) being modified with one or more hydrophilic side groups.

Abstract: Skin-contact products with a transpiration function such as medical devices or medicinal products, of which face masks, aspirators, ventilators, breast pumps or wound dressings are examples are described especially a skin-contact product with a transpiration function with an improved microclimate at a patient interface material-skin contact area. In an embodiment a material system (10, 20, 30) is described that comprises a hydrophobic silicone base material (11, 21, 31) and a hydrophilic silicone material (12, 22, 32) that is combined with the hydrophobic base material (11, 21, 31). At least a part of the hydrophilic material (12, 22, 32) is in contact with a moist surface (50). The hydrophobic base material (11, 21, 31) provides mechanical and dynamical stability of the material system (10, 20, 30). The hydrophilic material (12, 22, 32) allows for uptake or for diffusion of moisture away from moist surface (50).

Abstract: An elastomeric stamp has a bulk surface from which protruding features extend. A barrier layer covers the bulk surface and the protruding features. After applying an ink solution to the elastomeric stamp and drying the elastomeric stamp, the elastomeric stamp is brought into contact with a surface of a first substrate. The surface of the first substrate has a high affinity with the ink molecules, which is utilized to effectively remove the ink molecules from the contact surfaces of the protruding features. Subsequently, the elastomeric stamp is brought into contact with the surface of a second substrate. Ink molecules are transferred from the edges of the protruding features to the surface of a second substrate, thus forming an ink pattern in the form of a self assembled monolayer on this surface.

Abstract: This invention relates to a rubbery or elastomeric polymer material taking up more than 5% by weight of water and at most 500% by weight of water after immersion in demineralized water at room temperature for a sufficient time to reach saturation, comprising: (a) repeating units from one or more hydrophobic organic monomers, and (b) repeating units from one or more monomers (a) being modified with one or more hydrophilic side groups. The rubbery or elastomeric polymer material may be in the form of a sheet, a foam, a coating adapted for adhesion to a substrate, or a fiber. This invention also relates to processes, polymerizable compositions, and foaming compositions for producing such rubbery or elastomeric polymer materials.

Abstract: A cushion member for a user interface device is provided. The cushion member is structured to provide a load distribution functionality responsive to the cushion member being donned by the user, wherein at least a portion of the cushion member has a local stiffness of less than or equal to 100 kPa/mm responsive to a stress increase on the cushion member of 1 kPa-15 kPa.

Abstract: The present invention relates to a method of forming iron oxide nanoparticles comprising the steps of (a) suspending iron oxide/hydroxide and oleic acid or a derivative thereof in a primary organic solvent; (b) increasing the temperature of the suspension by a defined rate up to a maximum of 340° C. to 500° C.; (c) aging the suspension at the maximum temperature of step (b) for about 0.5 to 6 h; (d) cooling the suspension; (e) adding a secondary organic solvent; (f) precipitating nanoparticles by adding a non-solvent and removing excess solvent; (g) dispersing said nanoparticles in said secondary organic solvent; (h) mixing the dispersion of step (g) with a solution of a polymer; and (i) optionally removing said secondary organic solvent.

Abstract: The present invention relates to a method of forming an iron oleate complex comprising the steps of: (a) dissolving an oleate in a low-order alcohol solvent at a temperature of about 35° C. to 65° C.; (b) adding a non-polar solvent to the solution of step (a); (c) adding an iron salt dissolved in a low-order alcohol to the solution of step (b); (d) agitating the solution of step (c) at a temperature of about 50° C. for at least 5 min; (e) cooling the reaction mixture of step (d) to a temperature of about 15° C. to 30° C.; (f) optionally filtering the reaction mixture of step (e); (g) separating the non-polar solvent phase from the low-order alcohol phase; (h) washing and drying the non-polar solvent phase; (i) removing volatiles from the non-polar solvent phase of step (h) by evaporation; and (j) mixing the product of step (i) with a polar solvent to yield a solid iron oleate complex.

Abstract: The present invention relates to a composition comprising a shell structure forming a cavity, wherein said shell structure comprises a drug and wherein said composition is associated with at least one contrast agent; wherein said shell structure is capable of releasing its contents into the exterior upon the application of an external stimulus and wherein said contrast agent comprises magnetic particles which are capable of being detected by Magnetic Particle Imaging (MPI), wherein at least more than 5% (w/w) of the magnetic particles comprised in said contrast agent have a magnetic moment of at least ?18 m 2 A, 10 wherein said magnetic particles are preferably composed of Fe, Co, Ni, Zn or Mn or alloys thereof or oxides of any of these.

Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an alkene or alkyne dienohile.

Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other a cyclooctene or cyclooctyne.

Abstract: The invention relates to a method of MR imaging of at least a portion of a body of a patient placed in an examination volume of an MR device. The object of the invention is to improve CEST contrast enhanced imaging. The method of the invention comprises the following steps: a) saturation of nuclear magnetization of exchangeable protons of a CEST contrast agent administered to the patient by subjecting the portion of the body to at least one frequency-selective saturation RF pulse matched to the MR frequency of exchangeable protons of the CEST contrast agent, wherein the saturation period, i.e.

Abstract: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.

Abstract: The present invention is concerned with etchant or etching solutions and additives therefor, a process of preparing the same, a process of patterning a substrate employing the same, a patterned substrate thus prepared in accordance with the present invention and an electronic device including such a patterned substrate. An etchant solution according to the present invention for patterned etching of at least one surface or surface coating of a substrate comprises nitric acid, a nitrite salt, a halogenated organic acid represented by the formula C(H)n(Hal)m[C(H)o(Hal)p]qC?2H, where Hal represents bromo, chloro, fluoro or b iodo, where n is 0, 1, 2 or 3, and m is 0, 1, 2 or 3, with the proviso that m+n=3; o is 0 or 1, p is 1 or 2, with the proviso that o+p=2; q is 0 or 1, with the proviso that q+m=1, 2, 3 or 4; and balance water.